SCHEMBL5562010

SCHEMBL5562010

CCCCCCCC/C=C\CCCCCCCCOC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EHMT1 Q9H9B1 1/20 0.67
RXFP1 Q9HBX9 1/20 0.62
ADORA1 P30542 3/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
P2RY1 P47900 2/20 0.58
DNPH1 O43598 1/20 0.58
PRKAB2 O43741 1/20 0.58
TRPM2 O94759 1/20 0.58
LDHA P00338 1/20 0.58
ADRB2 P07550 1/20 0.58
FBP1 P09467 1/20 0.58
SRC P12931 1/20 0.58
P2RY2 P41231 1/20 0.58
PRKAG1 P54619 1/20 0.58
PRKAA2 P54646 1/20 0.58
PDE4D Q08499 1/20 0.58
KCNH2 Q12809 1/20 0.58
PRKAA1 Q13131 1/20 0.58
PDE3A Q14432 1/20 0.58
TAS1R3 Q7RTX0 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10865966 0.95 EHMT1 (0.74) EHMT1RXFP1ADORA1SMN1; SMN2P2RY1
SCHEMBL1920531 0.95 EHMT1 (0.74) EHMT1RXFP1ADORA1SMN1; SMN2P2RY1
SCHEMBL9231760 0.94 EHMT1 (0.76) EHMT1RXFP1ADORA1SMN1; SMN2P2RY1
SCHEMBL1637468 0.94 EHMT1 (0.76) EHMT1RXFP1ADORA1SMN1; SMN2P2RY1
SCHEMBL8671033 0.91 EHMT1 (0.74) EHMT1RXFP1ADORA1SMN1; SMN2P2RY1
SCHEMBL29936475 0.91 EHMT1 (0.74) EHMT1RXFP1ADORA1SMN1; SMN2P2RY1
SCHEMBL8671037 0.91 EHMT1 (0.74) EHMT1RXFP1ADORA1SMN1; SMN2P2RY1
SCHEMBL8005428 0.88 P2RY1 (0.60) EHMT1ADORA1SMN1; SMN2P2RY1DNPH1
SCHEMBL10791195 0.88 P2RY1 (0.69) ADORA1SMN1; SMN2P2RY1DNPH1PRKAB2
SCHEMBL2534140 0.87 EHMT1 (0.70) EHMT1RXFP1ADORA1SMN1; SMN2P2RY1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070160554-A1 Acyl ribonucleosides and acyl deoxyribonucleosides, compositions of, and methods of making same COGNIS IP MANAGEMENT GMBH (DE) 2007-07-12 US claimed
EP-1680435-A1 ACYL RIBONUCLEOSIDES AND ACYL DEOXYRIBONUCLEOSIDES Cognis IP Management GmbH (DE) 2006-07-19 EP claimed
WO-2005049633-A1 ACYL RIBONUCLEOSIDES AND ACYL DEOXYRIBONUCLEOSIDES COGNIS IP MANAGEMENT GMBH (DE) 2005-06-02 WO claimed
US-20070160554-A1 Acyl ribonucleosides and acyl deoxyribonucleosides, compositions of, and methods of making same COGNIS IP MANAGEMENT GMBH (DE) 2007-07-12 US disclosed
EP-1680435-A1 ACYL RIBONUCLEOSIDES AND ACYL DEOXYRIBONUCLEOSIDES Cognis IP Management GmbH (DE) 2006-07-19 EP disclosed
WO-2005049633-A1 ACYL RIBONUCLEOSIDES AND ACYL DEOXYRIBONUCLEOSIDES COGNIS IP MANAGEMENT GMBH (DE) 2005-06-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070160554-A1 Acyl ribonucleosides and acyl deoxyribonucleosides, compositions of, and methods of making same RNASEL, RNASEH1, DUT EHMT1 1497/4885RXFP1 4394/4885ADORA1 415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.